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Abstract 
Cocaine users consistently develop working memory (WM) impairments but the mediating molecular 
mechanisms are unknown so far. Recent evidence suggests that the serotonin (5-HT) system is altered by 
chronic cocaine use, while also being involved in WM processing. Thus, we investigated the effects of 
genetic variations impacting 5-HT activity and of peripheral 5-HT transporter (5-HTT) mRNA expression 
on WM performance in cocaine users and stimulant-naïve controls.  
Two-hundred-twenty participants (126 cocaine users, 94 controls) were assessed with visuospatial, 
spatial and verbal WM tasks, genotyped for the length polymorphism in the promoter region of the 5-
HTT (5-HTTLPR), the variable number of tandem repeats in the second intron of the 5-HTT (VNTR In2), 
two single nucleotide polymorphisms (rs4570625, rs1386497) in the tryptophan hydroxylase-2 (TPH2) 
gene and quantified for peripheral 5-HTT mRNA expression in whole blood samples. 
Several significant gene*environment interactions between 5-HT genotypes and cocaine use on WM 
emerged: In cocaine users, the long/long (5-HTTLPR), 9+10/9+10 (VNTR In2) and C/C (TPH2 rs1386497) 
genotypes were risk-alleles for WM impairments, while in healthy controls these polymorphisms were 
associated with improved WM performance. Analogously, high 5-HTT mRNA levels were associated with 
worse executive WM performance in cocaine users but with increased performance in controls. 
These gene*environment interactions suggest that the 5-HT system plays an important role in the 
development of cognitive deficits in chronic cocaine users. Hence, pharmacological compounds targeting 
5-HT neurotransmission might be promising for the treatment of cognitive deficits in cocaine 
dependence. 
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Introduction 
Cocaine users consistently show impairments in several cognitive domains such as attention, working 
memory (WM), declarative memory, and executive functions (Beveridge et al, 2008; Goldstein et al, 
2004; Vonmoos et al, 2013). Among these, WM seems to be affected first and to show greatest deficits 
after ongoing use (Jovanovski et al, 2005; Vonmoos et al, 2013). Thus, WM was claimed to be particularly 
susceptible to cocaine consumption (Robbins and Arnsten, 2009; Vonmoos et al, 2013). Recent 
longitudinal data furthermore suggest that WM deficits in cocaine users are likely drug-induced rather 
than predisposed (Vonmoos et al, 2014). However, the molecular mechanism by which such cognitive 
deficits develop, remains unclear so far. 
Increasing evidence from rodent and human studies suggests that the serotonin (5-HT) system plays an 
important role in WM processing (Fitzgerald, 2011). For instance, altering 5-HT synthesis by tryptophan 
depletion revealed that 5-HT transmission positively correlates with activity in the prefrontal cortex (PFC) 
and with WM performance (Allen et al, 2006; Porter et al, 2003). These effects are assumed to be 
mediated by 5-HT2A and 5-HT1A receptors in the PFC (Puig and Gulledge, 2011; Williams et al, 2002). 
Moreover, in genetic studies, the length polymorphism (short vs. long allele) in the promoter region of 
the serotonin transporter (5-HTT) gene (5-HTTLPR, SLC6A4) and more recently a single nucleotide 
polymorphism (SNP, rs4570625) in the promoter region of the tryptophan hydroxylase 2 (TPH2) gene 
have been found to influence WM performance (Bosia et al, 2010; Homberg and Lesch, 2011; Reuter et 
al, 2008; Zilles et al, 2012). This is plausible because the 5-HTT terminates 5-HT from the synaptic cleft by 
5-HT reuptake after synaptic signaling (Glatz et al, 2003; Lesch et al, 1996) and the TPH2 (the rate-
limiting enzyme of 5-HT synthesis) appears to facilitate 5-HT neurotransmission by increasing 5-HT 
availability (Kim et al, 2002). However, results of the genetic studies are inconsistent. Some authors 
found the long allele of 5-HTTLPR to be associated with superior WM performance (Bosia et al, 2010; 
Zilles et al, 2012), whereas others claimed the short allele to be associated with improved performance 
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(Anderson et al, 2012; Enge et al, 2011). It was argued that these conflicting results may either be due to 
a task-specificity of the 5-HTTLPR (Anderson et al, 2012; Zilles et al, 2012), or due to undetected and 
moderating environmental factors (Zilles et al, 2012). 
The 5-HTTLPR has been intensively investigated regarding its potential impact on the risk for cocaine 
addiction but the results are mixed showing either and association of the long allele with cocaine 
dependence only in European patients (Patkar et al, 2002) or an association of the short allele with 
cocaine/heroin dependence in Americans of African descent (Enoch et al, 2011) or no significant 
associations of the 5-HTTLPR with cocaine addiction and treatment outcome (Mannelli et al, 2005; 
Patkar et al, 2001; Tristan-Noguero et al, 2013). Also polymorphisms in the TPH2 gene have been 
analyzed but they did not show any associations with cocaine dependence (Dahl et al, 2006). 
Several rodent studies have shown that 5-HT neurotransmission is drastically increased after acute and 
reduced after chronic cocaine administration (for a review see: Muller and Homberg, 2015). Positron 
emission tomography (PET) studies in monkeys showed increased 5-HTT availability in frontal areas after 
chronic cocaine administration, whereas PET studies in humans revealed that chronic use is associated 
with reduced 5-HT1B receptor binding in the PFC (Gould et al, 2011; Matuskey et al, 2013). In addition, 
studies in rats demonstrated that the TPH2 activity in the raphe nucleus increases after chronic cocaine 
administration (Vrana et al, 1993). In their comprehensive review on the role of 5-HT in drug addiction, 
Müller and Homberg (2015) concluded that chronic cocaine use might induce an increase in terminal 5-
HTT function with reduced extracellular 5-HT levels in cortical areas. Subsequent acute cocaine 
challenges may then encounter more terminal and less somatodendritic 5-HTT targets and, thus, induce 
an intensified cortical 5-HT increase further reiterating the change in 5-HT function. 
The aim of this study was to investigate whether 5-HTT and TPH2 polymorphisms are associated with 
WM deficits in cocaine users. As outlined above, polymorphisms in 5-HTT and TPH2 genes (Bosia et al, 
2010; Homberg and Lesch, 2011; Reuter et al, 2008; Zilles et al, 2012) as well as chronic cocaine use 
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(Muller and Homberg, 2015) are assumed to impact 5-HT neurotransmission. Given that the 5-HT system 
has been linked to WM performance (Allen et al, 2006; Porter et al, 2003), we hypothesized that 5-HTT 
and TPH2 polymorphisms interact with cocaine use regarding WM performance. In addition to the 
above-mentioned 5-HTTLPR and the TPH2 polymorphism (rs4570625), we further examined the variable 
number tandem repeats polymorphism within intron 2 of the 5-HTT (VNTR In2) and a second promising 
SNP in the TPH2 gene (rs1386497). The VNTR In2 was chosen because it is assumed to have 5-HTT 
transcription regulating properties and the rs1386497 was selected due to its association with cognitive 
deficits in attention deficit hyperactivity disorder (ADHD) (MacKenzie and Quinn, 1999; Manor et al, 
2008). Besides these polymorphisms, we measured 5-HTT (SLC6A4) mRNA expression in peripheral blood 
in order to detect potential interactions between 5-HTT and TPH2 genotype, 5-HTT gene expression and 
cocaine use. Finally, because of the inconsistent results of previous studies, we used various WM tasks in 
order to compare genotype effects for visuospatial, spatial, and verbal WM subdomains.  
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Materials and Methods 
Participants 
A total sample of 220 participants (126 chronic cocaine users and 94 stimulant-naïve controls) was 
investigated as part of the longitudinal Zurich Cocaine Cognition Study (ZuCo2St: (Vonmoos et al, 2013; 
Vonmoos et al, 2014)). Cocaine users were included if they indicated cocaine as their primary drug of 
choice, showed a use of >0.5g/month, and a maximum abstinence duration no longer than 6 months. 
Exclusion criteria for all participants were any current or previous neurological disorders or head injuries 
and use of prescription drugs affecting cognitive functioning. Additional exclusion criteria for the cocaine 
users were regular use of opioids or a polytoxic drug use pattern according to DSM-IV as well as any 
current or previous Axis-I DSM-IV psychiatric disorders with exception of cocaine and alcohol 
abuse/dependence, a history of depression, and ADHD. Specific exclusion criteria for the control group 
were regular drug use (lifetime >15 occasions) with the exception of nicotine dependence and occasional 
cannabis use and any current or previous Axis-I DSM-IV psychiatric disorder (American Psychiatric 
Association, 1994). Participants self-reports regarding drug use were controlled by toxicological analyses 
of urine and 6cm (if possible) hair samples (see also Table S1). More detailed information about 
selection, recruitment, and drug screenings have been presented in detail in our previous work (Hulka et 
al, 2014; Preller et al, 2013; Vonmoos et al, 2013). The presented study was approved by the Cantonal 
Ethics Committee of Zurich. All participants provided written informed consent prior to the study and 
were financially compensated for their participation. 
 
Procedure 
All participants were examined by trained psychologists using a Structural Clinical Interview (SCID-
I)(Wittchen et al, 1997) according to DSM-IV. Drug use was assessed by using a structured and 
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standardized Interview for Psychotropic Drug Consumption (Quednow et al, 2004). Subsequently, 
participants underwent a battery of neuropsychological evaluations including the Spatial Working 
Memory task (SWM) and the Paired Associates Learning task (PAL) from the Cambridge 
Neuropsychological Test Automated Battery (CANTAB, www.cambridgecognition.com)(Strauss et al, 
2006) as well as the Letter Number Sequencing Task (LNST) (Wechsler, 1997). In order to draw 
conclusions about global WM processes, the three main parameters of these tests (SWM total errors, 
PAL first trial memory score, LNST correct responses) were z-transformed (based on means and standard 
deviations of the control group) and incorporated into a global WM capacity index (as described in our 
previous work: Vonmoos et al, 2013). To additionally investigate an executive WM component, we 
separately analyzed the SMW strategy score that is thought to primarily reflect executive functioning, i.e. 
strategic planning (Owen et al, 1990). 
 
Genotyping and mRNA Quantification 
The 5-HTTLPR, VNTR In2, and TPH2 polymorphisms were determined as described in the Supplemental 
Material. The 5-HTTLPR was assessed in its bi-allelic (short vs. long allele) instead of its tri-allelic form (LA 
vs. LG, SA and SG, see: Hu et al, 2006) in order to compare our results with previous studies on the 
effects of 5-HTTLPR on WM. Furthermore, subjects with 9 copies (2.7%) in the VNTR In2 were pooled 
with subjects carrying 10 copies resulting in three genotype groups: 9+10/9+10 vs. 9+10/12 vs. 12/12. 
Also, subjects with the rare T/T genotype (6,2%) of TPH2 rs4570625 and the rare C/C genotype (3.6%) in 
TPH2 rs1386497 were pooled with subject with the G/T and the A/C genotype, respectively, resulting in 
the two genotype groups: G/G vs. G+T/T and A/A vs. A+C/C.  
Total RNA was isolated from whole blood using the RNA isolation NucleoSpin RNA Blood in combination 
with the NucleoSpin RNA/DNA Buffer Set according to the manufacturer’s recommendation (Macherey-
Nagel AG, Oersingen, Switzerland). Total RNA samples were spectrophotometrically scanned (NanoVue, 
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GE Healthcare Life Sciences) to obtain the A260/A280 of >1.9 and concentration levels. Additionally, for 
RNA quality resulting with RIN (RNA integrity number) values, all samples were measured on the 
automated electrophoresis system (Experion, BioRad Co., Hercules, CA, USA). Quantitative real-time RT-
PCR was conducted for 5-HTT (SLC6A4) and six additional reference genes (ACTB, GAPDH, ALAS1, 
RPL13A, PPIA, and 18S ribosomal RNA) as described previously (Grunblatt et al, 2009). Total RNA (500 
ng) from each sample was reverse transcribed using iScript cDNA synthesis kit (BioRad Co., Hercules, CA, 
USA). Each amplification was performed in a total volume of 20μl containing 5μl QuantiTect SYBR Green 
PCR kit (Qiagen) and the specific primer mix (PrimerAssay- Qiagen). PCR conditions were run according 
to manufacturer’s manual (Qiagen). A melting point analysis was conducted for each assay to confirm 
specificity of PCR products and all PCR reactions were run in triplicates. The program LinRegPCR 
(www.hartfaalcentrum.nl) was used to determine the PCR efficiency. Gene expression and normalization 
analysis with the most stable reference genes was conducted using the QBase plus software (Biogazelle) 
(Vandesompele et al, 2002). The software detected that the reference gene RPL13A was least stable and 
therefore this gene was excluded and normalization analysis was conducted using the five other 
reference genes. We also tried to determine TPH2 mRNA but the melting point analysis revealed an 
insufficient quality of the PCR products indicating that the TPH2 mRNA was degraded. 
 
Statistical Analyses 
Global and task-specific WM effects were analyzed separately for each polymorphism using analyses of 
variance (ANOVA) with the factors: group (cocaine users vs. controls) and genotype (5-HTTLPR and VNTR 
In2: threefold, TPH2 rs4570625 and rs1386497: twofold, see above). Additionally, analyses of covariance 
(ANCOVA) with the covariates age, years of education, BDI, and ADHD were calculated to investigate 
possible influences of these factors. The influence of 5-HTT mRNA expression on WM performance was 
investigated using Pearson correlations, whereas mRNA expression*genotype interactions were 
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examined using ANCOVAs with mRNA expression as the covariate. Results were considered significant if 
p<.05 after correction for multiple comparisons using the Hochberg method (Hochberg, 1988). 
Hochberg’s procedure (a step-up modification of the Bonferroni method) tests each partition hypothesis 
using all the order statistics by formulating a sequence of critical values based on Simes’ inequality. 
Statistical analyses were conducted with SPSS (Version 20.0), testing of linkage disequilibrium (LD) 
between polymorphisms was performed with the software Haploview (Barrett et al, 2005) and 
associations between polymorphisms and cocaine use was analyzed with the Armitage’s Trend Test. 
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Results 
Demography and association analysis 
Cocaine users and stimulant-naïve controls did not differ regarding age and sex distribution. However, 
cocaine users had significantly fewer years of education, higher scores in the Beck Depression Inventory 
(BDI) and higher scores of ADHD than controls (see Table 1). Beyond these group differences, we did not 
find any significant genotype or group*genotype interaction effects on BDI (all p>.05) or ADHD (all 
p>.05). For additional information on the substance use of both groups see Table S1 in the Supplemental 
Material. Genotype frequencies of all four polymorphisms (see also Table S2) were distributed in 
accordance with the Hardy-Weinberg Equilibrium (HWE) and the SNPs rs4570625 and rs1386497 were 
found to be in minimal Linkage Disequilibrium (LD, D’=1.0, LOD: 5.16, r2=0.06). None of the 
polymorphisms was associated with cocaine use per se (Table S2) and within the group of cocaine users 
genotype groups did not differ regarding cocaine consumption (Table S3).  
 
Global WM Capacity 
Global WM performance was affected by a significant main effect of the factor group, whereas the factor 
genotype alone was not significant in any analysis (Table 2). However, there were significant 
group*genotype interactions for all variants except for TPH2 rs4570625, which nonetheless showed a 
similar trend. Cocaine users revealed a worse WM performance compared to controls as shown 
previously for this sample (Vonmoos et al, 2013), whereby 5-HTTLPR, VNTR In2, and TPH2 rs1386497 
genotype inversely affected WM in cocaine users and controls (Figure 1). These effects remained 
significant after correction for multiple comparisons (see Table 2) and even when age, years of 
education, BDI and ADHD were introduced as covariates (5-HTTLPR: F(2,207)=5.28, pcor<.05; VNTR In2: 
F(2,202)=7.29, pcor<.01; TPH2 rs1386497: F(1,207)=5.14, pcor<.05). Among the covariates, age showed a 
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significant main effect in the ANCOVAs of all three significant polymorphisms (all pcor<.001), whereas 
years of education was only significant for 5-HTTLPR and TPH2 rs1386497 (both pcor<.05).  
 
WM Subdomains and Executive WM 
Table 2 further reveals that the above described main effects of group and the group*genotype 
interactions were also found within the spatial, verbal, and visuospatial WM subdomains and in the 
executive WM parameter SMW strategy. In SWM strategy, we observed similar significant 
group*genotype interactions with 5-HTTLPR and VNTR In2 genotype as shown for global WM above (see 
Figure S1). Regarding the spatial WM subdomain (CANTAB SWM total errors), significant interactions 
(corrected for multiple testing) were observed for VNTR ln2 and TPH2 rs1386497 genotypes while 5-
HTTLPR and TPH2 rs4570625 displayed strong trends. LNST also showed moderate interaction effects of 
5-HTTLPR, VNTR ln2 genotypes and TPH2 rs1386497 with group, which remained trends after multiple-
test correction. Finally, in CANTAB PAL, no interaction effects were strong enough to survive correction 
for multiple testing. It should be noted that all subdomains (with exception of PAL regarding TPH2 
rs1386497) showed the same pattern of group*genotype interaction as illustrated for the global WM 
capacity index in Figure 1 (see Figure S2).  
 
5-HTT mRNA expression 
Peripheral mRNA expression did not differ between controls and cocaine users and across genotype 
groups (see Table S4). Also, correlations between 5-HTT mRNA expression and WM performance did not 
reveal any significant results, neither in the total sample nor in both subgroups. However, using a median 
split of the mRNA expression (high vs. low expression) together with the factor group in a two-way 
ANOVA revealed a significant group*mRNA expression interaction (F(1,107)=6.36, pcor>.05, corrected for 
age and years of education) in SWM strategy (Figure 2). Additionally, by including mRNA expression as a 
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covariate in an ANCOVA together with group and genotype, we found significant three-way interactions 
of group*genotype*mRNA expression for VNTR In2 in the global WM capacity index (F(4, 96)=5.04, 
pcor<.01), in LNST (F(4, 96)=3.93, pcor<.05) and in PAL (F(4, 96)=3.70, pcor<.05), for TPH2 rs4570625 in the 
global WM capacity index (F(2, 101)=9.15, pcor<.001), in LNST (F(2, 101)=4.85, pcor<.05), in PAL (F(2, 
101)=7.16, pcor<.01) and in SWM strategy (F(2, 101)=5.51, pcor<.05) and for TPH2 rs1386497 in LNST (F(1, 
207)=4.401, pcor<.05). These threefold interactions (see Figure S3-S7) were mainly explained by a general 
interaction between gene expression and group mirroring the group*genotype interaction shown above 
(see Figure 2). 
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Discussion  
The present study was designed to investigate whether WM impairments in cocaine users are mediated 
by polymorphisms within the 5-HT system. We demonstrated that three of four investigated 5-HT-
impacting polymorphisms (5-HTTLPR, VNTR In2, TPH2 rs1386497) mediate WM performance and that 
their effects on WM depend on cocaine use of participants. 
Concerning the 5-HTTLPR polymorphism, we found the long/long genotype to be a risk factor for the 
presence of WM impairments in cocaine users, while it was associated with improved WM performance 
in healthy controls. Even though, the effects of 5-HTTLPR on 5-HT neurotransmission in humans is a 
subject of controversial debate, our results can be interpreted in consideration of previous animal 
studies. Carriers of the short allele of the 5-HTTLPR polymorphism are assumed to display decreased 
cerebral 5-HTT expression and thus decreased 5-HT reuptake after synaptic signaling (Glatz et al, 2003; 
Lesch et al, 1996). However, carrying the short allele does not appear to result in increased 5-HT 
neurotransmission. In fact, increasing evidence from studies using 5-HTT knock-out mice suggests that 
having the short allele results in decreased 5-HT neurotransmission based on long-term developmental 
effects of reduced 5-HT reuptake on cell number, firing rate, and postsynaptic receptor sensitivity (Kim et 
al, 2005; Lira et al, 2003). Assuming, thus, that healthy control subjects carrying the short/short 
genotype have lower 5-HT activity and a reduced clearance rate after activation than long/long controls, 
our results are consistent with previous studies showing decreased cognitive functioning in participants 
with lower 5-HT levels (Allen et al, 2006; Fitzgerald, 2011; Murphy et al, 2002; Porter et al, 2003; Rogers 
et al, 2003). However, this interpretation is speculative because there is no consensus on the effects of 
5-HTTLPR on 5-HT neurotransmission in humans so far. For instance, two molecular imaging studies 
employing PET in humans did not find an association between the 5-HTTLPR genotype and 5-HTT binding 
(Murthy et al, 2010; Shioe et al, 2003), while two other PET studies showed increased 5-HTT densities in 
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putamen and midbrain, respectively, of long allele carriers (Praschak-Rieder et al, 2007; Reimold et al, 
2007). 
In cocaine users, carriers of the short/short genotype showed comparable WM performance as 
short/short genotype carriers of the controls. This finding is plausible considering the effects of cocaine 
use on the 5-HT system. Chronic cocaine administration is postulated (Muller and Homberg, 2015) to 
simultaneously result in an overexpression of 5-HTT at terminal sites of neurons and in an attenuated  
expression of 5-HTT at somatodendritic sites (Gould et al, 2011; Muller et al, 2002; Muller and Homberg, 
2015). By this, chronic cocaine consumption is thought to result in a chronically reduced 5-HT neuronal 
activity together with a more efficient removal of 5-HT from the synaptic cleft in terminal areas of the 5-
HT projections. The 5-HTTLPR long/long genotype probably displays more 5-HTT under basal conditions, 
which may offer more target sites for cocaine interactions. One may, therefore, speculate that 5-HTT 
adaptations after chronic cocaine use are stronger in the long/long than in the short/short genotype. 
This may result in a stronger reduction of basal 5-HT activity in the long/long genotype and, thus, in more 
pronounced WM deficits. It could thus be assumed that, under such conditions, having a genetically 
limited 5-HTT expression protects against cocaine-induced adaptations of the 5-HTT function. Hence, this 
view is supported by our data indicating unaffected WM performance in cocaine users carrying the short 
allele.  
Our results regarding the 5-HTTLPR polymorphism seem to confirm the hypothesis that increased 5-HT 
activity is associated with improved cognitive functioning (in our case WM) in healthy controls (Murphy 
et al, 2002; Rogers et al, 2003). Moreover, we went one step further by showing that environmental 
factors (such as cocaine use) are able to moderate the direction of the polymorphism effects. This finding 
is especially interesting considering the conflicting results of previous studies suggesting that the effects 
of the 5-HTTLPR might be task-specific (Anderson et al, 2012; Zilles et al, 2012). However, we were able 
to demonstrate consistent genotype effects across WM tasks measuring spatial (SWM), verbal (LNST), 
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and visuospatial (PAL) WM subdomains (see Table 1 and Figures S2). Hence, we propose that undetected 
gene*environment interactions (such as the discovered genotype-cocaine interaction) could provide an 
explanation for the previously conflicting results. 
Our findings are further supported by the 5-HTT mRNA expression results. Analyzing peripheral mRNA 
expression in whole blood samples, we found a similar group*genotype interaction effect of 5-HTTLPR in 
form of an interaction of group*mRNA expression also indicating higher WM performance in controls 
with increased 5-HTT expression and lower WM performance in cocaine users with increased 5-HTT 
expression. This is consistent with previous studies showing that 5-HTT mRNA expression can be used to 
replicate 5-HTTLPR genotype findings (Gardner et al, 2009). 
Regarding the two SNPs in the TPH2 gene, we were not able to clearly replicate previous studies 
postulating the rare T/T genotype of rs4570625 to be associated with lower WM performance (Reuter et 
al, 2008). However, we found a significant interaction between TPH2 rs1386497 (which is in LD with 
rs4570625) and cocaine use. The A/A genotype of rs1386497 was associated with lower performance in 
cocaine users, whereas healthy controls carrying the A/A genotype showed higher WM performance. 
Tryptophan hydroxylase is a rate-limiting enzyme of the 5-HT synthesis (Kim et al, 2002) and although 
the rs1386497 has not yet been reported in relation to WM, its A allele has been associated with ADHD 
and cognitive deficits in ADHD (Manor et al, 2008; Sheehan et al, 2005). Interestingly, we reported in our 
previous work that the co-occurrence of cocaine consumption and ADHD had a particularly negative 
impact on cognitive functioning (Vonmoos et al, 2013). However, including ADHD as covariate still 
revealed an ADHD-independent interaction effect of TPH2 rs1386497 and cocaine use on WM 
performance. 
Concerning the VNTR In2, we demonstrated that controls revealed higher WM performance when 
carrying the short allele (9+10/9+10 copies) compared with carriers of the long allele (12/12 copies). In 
cocaine users, again, this pattern was inverted. It has been proposed that the VNTR In2 polymorphism 
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acts as a transcriptional regulator of the 5-HTT expression but its exact effect is not fully clear yet 
(MacKenzie and Quinn, 1999). Comparing our findings of the 5-HTTLPR with the findings of the VNTR In2 
reveals that the long/long genotype of 5-HTTLPR seems to have a similar effect on WM as the 12 copies 
variant of the VNTR In2. This specific pattern has already been found by other genetic studies with 
psychiatric patients suffering from personality and psychosomatic disorders (Garcia et al, 2010; Kirtak et 
al, 2008). 
In sum, we presented evidence that genetic variations, putatively influencing 5-HT activity, mediate the 
development of WM impairments in cocaine users and that increased 5-HTT expression in the periphery 
goes along with these WM deficits. Our results support the view that chronic cocaine use enhances 
terminal 5-HTT function and that this enhanced activity, together with adaptations of postsynaptic 5-HT 
receptors, is responsible for the cognitive decline seen in cocaine users (Muller and Homberg, 2015). 
Alternatively, it might be speculated that specific 5-HTT polymorphisms, such as 5-HTTLPR and VNTR In2, 
impact the protein tertiary structure of the 5-HTT leading to a changed affinity to cocaine. In that case, 
genetic variations could also impact the acute effects of cocaine on 5-HT reuptake inhibition. Future 
studies should therefore investigate whether there are genotype differences in the acute effects of 
cocaine administration on a neuropharmacological as well as on a behavioral level. In addition, 
functional and molecular imaging techniques might be a promising approach to get a deeper 
understanding of the mechanisms underlying the cocaine-genotype interaction on WM. 
In conclusion, we demonstrated that three 5-HT-impacting polymorphisms are risk-alleles for the 
development of WM deficits in cocaine users. Hence, pharmacological compounds targeting 5-HT 
neurotransmission might be a promising treatment option of WM deficits in cocaine addiction. 
Additionally, our results regarding the 5-HTTLPR and the VNTR In2 polymorphisms in healthy controls 
seem to confirm the hypothesis (Fitzgerald, 2011) that increased 5-HT activity improves cognitive 
functioning (in our case WM). Finally, the discovered gene*environment interaction (i.e. cocaine use 
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moderated genotype effects) indicates that the complexity of the 5-HT systems requires us to discover 
other relevant factors to fully understand the involvement of 5-HT in WM processing. 
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Tables 
 
Table 1 Demographic data of healthy controls and cocaine users (means and SD). 
 
Demographic Data Controls (n=94) Cocaine users (n=126) t-test/Χ2 df p 
      
        
Age, mean (SD) 30.0 (8.8) 30.1 (8.9) -0.1 218 0.917 
Sex (male / female) 68 / 26 91 / 35 0.0 1 0.554 
Years of education, mean (SD) 10.7 (1.8) 10.2 (1.7) 2.1 218 0.041 
BDI Score, mean (SD) 4.2 (4.0) 8.6 (7.1) -5.8 204.2 0.000 
ADHD DSM-IV Score, mean (SD) 7.9 (5.0) 14.4 (9.4) -6.5 198.7 0.000 
              
 
BDI: Beck Depression Inventory, ADHD: Attention Deficit Hyperactivity Disorder 
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Table 2 Analyses of variance for global working memory capacity, working memory subdomains, and 
executive working memory across all investigated polymorphisms. 
 
 
LNST: Letter-Number-Span-Task, PAL: Pair Associated Learning, pncor: uncorrected p-values, pcor: p-values corrected 
for multiple comparisons, SWM: Spatial Working Memory, WM: working memory 
  
5-HTTLPR VNTR In2 TPH2 (rs4570625) TPH2 (rs1386497)
F df pncor ηp2 pcor F df pncor ηp2 pcor F df pncor ηp2 pcor F df pncor ηp2 pcor
Global WM Capacity
Group 11.96 1 .001 .054 .002 26.48 1 .000 .114 .000 23.59 1 .000 .103 .000 10.78 1 .001 .049 .001
Genotype 0.47 2 .626 .004 .999 0.52 2 .593 .005 .999 0.13 1 .724 .001 .999 0.07 1 .791 .000 .791
Group*Genotype 4.87 2 .009 .044 .018 6.54 2 .002 .060 .006 2.30 1 .131 .011 .131 6.24 1 .013 .029 .026
Spatial WM (SWM)
Group 5.39 1 .021 .025 .042 13.52 1 .000 .062 .001 14.29 1 .000 .065 .000 3.33 1 .069 .016 .069
Genotype 2.99 2 .053 .028 .212 0.70 2 .498 .007 .999 0.02 1 .899 .000 .899 0.33 1 .566 .002 .999
Group*Genotype 3.18 2 .044 .029 .088 4.02 2 .019 .038 .057 3.23 1 .074 .016 .074 11.15 1 .001 .050 .004
Verbal WM (LNST)
Group 7.93 1 .005 .036 .005 17.55 1 .000 .079 .000 16.04 1 .000 .072 .000 8.17 1 .005 .037 .009
Genotype 0.88 2 .417 .008 .999 0.91 2 .403 .009 .999 0.23 1 .635 .001 .999 0.03 1 .859 .000 .859
Group*Genotype 3.26 2 .040 .030 .120 3.75 2 .025 .035 .100 1.72 1 .191 .008 .191 4.08 1 .045 .019 .090
Visuospatial WM (PAL)
Group 6.68 1 .010 .031 .010 12.85 1 .000 .056 .001 9.68 1 .002 .045 .006 7.88 1 .005 .036 .011
Genotype 0.32 2 .727 .003 .999 0.28 2 .760 .003 .999 0.10 1 .755 .000 .999 0.03 1 .854 .000 .854
Group*Genotype 2.19 2 .115 .020 .345 3.22 2 .042 .030 .168 0.01 1 .909 .000 .909 0.06 1 .803 .000 .999
Executive WM (Strategy)
Group 0.63 1 .428 .003 .428 5.81 1 .017 .028 .068 5.39 1 .021 .026 .063 1.84 1 .177 .009 .354
Genotype 0.86 2 .427 .008 .999 3.07 2 .048 .029 .192 0.09 1 .766 .000 .999 0.00 1 .964 .000 .964
Group*Genotype 5.55 2 .004 .050 .016 4.88 2 .009 .045 .027 0.66 1 .417 .003 .417 1.84 1 .176 .009 .352
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Figure Legends 
Fig. 1: Global working memory capacity scores for the three polymorphisms with significant 
group*genotype interactions (mean and SE, z-transformed and corrected for age and years of 
education). Significant genotype effects (p<0.05) within each group are indicated with *, while trends for 
genotype effects (p<0.1) are indicated with (*). 
Fig. 2: Executive working memory function (Spatial Working Memory strategy scores) in cocaine users 
and controls stratified for high vs. low of 5-HTT mRNA expression (mean and SE, z-transformed and 
corrected for age and years of education). 
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Serotonin transporter and tryptophan hydroxylase gene variations mediate working memory deficit of cocaine users 
Michael M Havranek, Matthias Vonmoos, Christian P Müller, Jessica R Büetiger, Eve Tasiudi, Lea M Hulka, Katrin H Preller, Rainald Mössner, 
Edna Grünblatt, Erich Seifritz, Boris B Quednow 
 
Genotyping 
DNA for the SNP genotyping was extracted either from EDTA anticoagulated blood samples or from immortalized lymphoblastoids cell cultures 
after transforming the lymphocytes with Epstein‐Barr virus. The isolation of the DNA followed the QIAGEN protocol for the Blood & Cell Culture 
DNA Isolation Maxi Kit (QIAGEN, Hilden, Germany). To determine the 5‐HTTLPR, PCR was performed in a final solution of 10µl, using 12.5ng of 
DNA, 2.5mM dNTPs, 0.5µM of each primer (5`‐TCC TCC GCT TTG GCG CCT CTT CC‐3´ (forward primer); 5´‐TGG GGG TTG CAG GGG AGA TCC TG‐3´ 
(reverse primer)), 0.5 U of Taq polymerase from Qiagen with addition of 2µl Q‐solution. The initial denaturation step of five minutes at 95°C was 
followed by 40 cycles each of 95°C for 30 seconds, 65.5°C for 90 seconds and 72°C for 1 minute. PCR was terminated by a final extension step at 
72°C for 10 minutes. 7.5 µl of the PCR product were utilized to separate the 512bp (long‐) and 469 bp (short‐) alleles of the 5‐HTTLPR. 
For  the VNTR In2 polymorphisms, PCR was performed in a final solution of 10µl, using 12.5ng of DNA, 2.5mM dNTPs, 0.3µM of each primer ( 5´‐
GTC AGT ATC ACA GGC TGC GAG‐3´ (forward primer), 5´‐TGT TCC TAG TCT TAC GCC AGT G‐3´ (reverse primer)) and 0.5 U of Taq‐polymerase 
(Qiagen). The initial denaturation step of three minutes at 95°C was followed by 45 cycles each of 95°C for 30 seconds, 60°C for 30 seconds and 
72°C for 45 seconds. PCR was terminated by a final extension step at 72°C for 10 minutes. We took 7.5 µl of the resulting PCR product and 
separated the different alleles on a 2.5% LE agarose gel (Biozym, Hess. Oldendorf, Germany) by electrophoresis. The length of the alleles were: 
251bp (9x), 268bp (10x) and 302bp (12x), respectively. 
To determine the SNPs in the TPH2 gene (rs4570625, rs1386497), PCR was performed using 12.5ng of DNA and the SNP Genotyping Assays 
provided by Applied Biosystems (Foster City, CA, USA). The procedure followed the protocol for TaqmanSNP‐Genotyping with the use of 
Taqman Universal PCR MasterMix and No AmpErase UNG. Each of the assays consisted of the unlabeled forward and reverse primers and two 
reporters that were dye‐labeled with FAMTM and VIC and were designed for allelic discrimination of specific SNPs. Both alleles were scored in a 
single well by measuring the fluorescence at the end of the PCR using a Tecan Ultra 384 reader (Tecan, Crailsheim, Germany). Excitation‐ and 
emission‐wavelengths were 485 and 535 nm for the FAM‐labeled probes and 535 and 590 nm for the VIC‐labeled probes, respectively. 
   
Tab. S1: Substance use (means and SD). 
Substance use  Controls (n=94)  Cocaine users (n=126) 
           
Weekly nicotine use, cigarettes, mean (SD)  62.0 (66.5)  92.6 (75.4) 
Weekly alcohol dose, g, mean (SD)  123.6 (135.9)  180.9 (194.8) 
Weekly cocaine dose, g, mean (SD)  ‐  2.4 (5.1) 
Years of cocaine use, mean (SD)  ‐  7.0 (5.4) 
Cocaine hair analysis, pg/mg, mean (SD)    ‐  7804.9 (18713.9) 
       
Cumulative cocaine dose, g, mean (SD)  ‐  2109.6 (5799.7) 
           
 
   
Tab. S2: Genotype frequencies of all four investigated polymorphisms in total sample, in controls and in cocaine users (HWE = Hardy‐Weinberg 
Equilibrium). 
Polymorphism  Genotype frequencies %  Deviation from HWE?  in controls %  in users %  Association with group? 
        
           
5‐HTTLPR  L/L  33.2  33.0  33.3 
S/L  51.2  X2(1) = .498, p = .481  51.6  50.8  X2(1) = .00, p = .990 
S/S  15.7  15.4  15.9 
VNTR In2  12/12  37.3  35.2  38.8 
12/9+10  44.3  X2(1) = .707, p = .401  44.0  44.6  X2(1) = .64, p = .423 
9+10/9+10  18.4  20.9  16.5 
TPH2 (rs4570625)  G/G  62.4  63.6  61.5 
G/T  31.4  X2(1) = 1.508, p = .219  31.8  32.0  X2(1) = 1.07, p = .301 
T/T  6.2  4.5  6.6 
TPH2 (rs1386497)  A/A  71.6  68.5  75.0 
A/C  24.8  X2(1) = .584, p = .445  28.3  22.6  X2(1) = .25, p = .619 
C/C  3.6  3.3  2.4 
                     
 
   
Tab. S3: Cocaine use across genotype groups (cocaine hair analysis, pg/mg, and cumulative cocaine dose in g, means and SD). 
Cocaine use  Genotype  Cocaine hair analysis, pg/mg, mean (SD)  F  df, dferr  p 
        
5‐HTTLPR  L/L  8615 (17995)  0.280  2, 121  0.756 
S/L  6648 (17732) 
S/S  9887 (23440) 
VNTR In2  12/12  2039 (5583)  0.354  2, 116  0.703 
12/9+10  6907 (15986) 
9+10/9+10  9458 (24490) 
TPH2 (rs4570625)  G/G  6695 (21799)  0.901  1, 117  0.345 
G/T + T/T  10117 (21798) 
TPH2 (rs1386497)  A/A  7913 (17236)  0.000  1, 120  0.991 
A/C + C/C  7954 (22777) 
                  
Cocaine use  Genotype  Cumulative cocaine dose, g, mean (SD)  F  df, dferr  p 
        
5‐HTTLPR  L/L  2631 (6030)  0.393  2, 122  0.676 
S/L  2028 (6220) 
S/S  1226 (3461) 
VNTR In2  12/12  2039 (5583)  0.058  2, 117  0.944 
12/9+10  2374 (7036) 
9+10/9+10  1941 (2590) 
TPH2 (rs4570625)  G/G  2560 (7024)  0.767  1, 118  0.383 
G/T + T/T  1591 (3534) 
TPH2 (rs1386497)  A/A  1946 (5216)  0.287  1, 121  0.593 
A/C + C/C  2586 (5844) 
                  
Tab. S4: mRNA expression levels in controls and cocaine users and across genotype groups (means and SD). 
Peripheral 5‐HTT mRNA expression, mean (SD) 
mRNA expression  Genotype  in controls  in cocaine users  F  df, dferr  p 
            
        
5‐HTTLPR  L/L  1.28 (.58)  1.21 (.41)  Factor group  0.011  1, 106  0.916 
S/L  1.23 (.59)  1.20 (.59)  Factor genotype  0.161  2, 106  0.852 
S/S  1.27 (.80)  1.34 (.68) 
VNTR In2  12/12  1.24 (.75)  1.38 (.70)  Factor group  0.86  1, 102  0.77 
12/9+10  1.21 (.46)  1.05 (.40)  Factor genotype  1.165  2, 102  0.316 
9+10/9+10  1.30 (.67)  1.22 (.40) 
TPH2 (rs4570625)  G/G  1.17 (.60)  1.22 (.55)  Factor group  1.518  1, 105  0.221 
G/T + T/T  1.60 (.58)  1.24 (.44)  Factor genotype  3.389  1, 105  0.068 
TPH2 (rs1386497)  A/A  1.32 (.49)  1.21 (5.1)  Factor group  0.258  1, 105  0.612 
A/C + C/C  1.21 (.75)  1.21 (.55)  Factor genotype  0.214  1, 105  0.645 
                        
 
   
Figure S1 
 
Fig. S1: Executive WM scores for the three polymorphisms with significant group*genotype interactions in 5‐HTTLPRand VNTR In2 but not in 
TPH2 rs1386497 (mean and SE, z‐transformed and corrected for age and years of education). 
  
Figure S2 
A)  
B)  
C)  
Fig. S2: Spatial WM (A), verbal WM (B) and visuospatial WM scores (C) for 5‐HTTLPR, VNTR In2 and TPH2 rs1386497 (mean and SE, z‐
transformed and corrected for age and years of education). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3 
A)  
B)  
Fig. S3: Global WM scores for the mediansplit (low vs. high) of 5‐HTT mRNA expression in A) VNTR In2 and B) TPH2 rs4570625 (mean and SE, z‐
transformed and corrected for age and years of education).   
Figure S4 
 
Fig. S4: Spatial WM scores for the mediansplit (low vs. high) of 5‐HTT mRNA expression in TPH2 rs4570625 (mean and SE, z‐transformed and 
corrected for age and years of education). 
 
   
Figure S5 
A)   
B)   
 
C)   
Fig. S5: Verbal WM scores for the mediansplit (low vs. high) of 5‐HTT mRNA expression in A) VNTR In2, B) TPH2 rs1386497 and C) TPH2 
rs4570625 (mean and SE, z‐transformed and corrected for age and years of education). 
   
Figure S6 
 
Fig. S6: Visuospatial WM scores for the mediansplit (low vs. high) of 5‐HTT mRNA expression inTPH2 rs4570625 (mean and SE, z‐transformed and 
corrected for age and years of education). 
 
   
Figure S7 
 
Fig. S7: Executive WM scores for the mediansplit (low vs. high) of 5‐HTT mRNA expression inTPH2 rs4570625 (mean and SE, z‐transformed and 
corrected for age and years of education). 
 
